These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16546862)

  • 1. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
    Benasso M; Ponzanelli A; Merlano M; Numico G; Ricci I; Vigo V; Grossi F; Amadori D; Cavallo G; Capaccetti B; Taveggia P; Boni L; Rosso R
    Acta Oncol; 2006; 45(2):168-74. PubMed ID: 16546862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
    Hussain M; Salwen W; Kucuk O; Ensley J
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
    Benasso M; Numico G; Rosso R; Merlano M; Ricci I; Gentile A
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-46-S19-50. PubMed ID: 9427266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
    J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
    Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
    J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Baghi M; Hambek M; Wagenblast J; May A; Gstoettner W; Knecht R
    Anticancer Res; 2006; 26(1B):585-90. PubMed ID: 16739325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
    Rowland KM; Taylor SG; Spiers AS; DeConti RC; O'Donnell MR; Showel J; Stott PB; Milner LM; Marsh JC
    Cancer Treat Rep; 1986 Apr; 70(4):461-4. PubMed ID: 3698038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.